论文部分内容阅读
目的探讨血脂康胶囊对急性冠脉综合征患者血清超敏C反应蛋白的影响。方法将2010年6月-2011年12月就诊我院心内科治疗急性冠脉综合征的患者70例按就诊顺序分为两组，对照组给予辛伐他汀治疗，观察组在此基础上给予血脂康胶囊治疗，治疗6个月以后，观察比较两组患者临床疗效和血清中超敏C反应蛋白数值变化。结果观察组治疗后血清超敏C反应蛋白数值与治疗前和对照组治疗后比较，有统计学意义（P<0.05）；临床症状改善观察组显效19、好转15例、无效1例、总有效率为97.1%；对照组显效13例、好转17例、无效5例、总有效率为85.7%，两组数据比较有统计学意义（P<0.05）；心电图改善观察组显效20例、好转13例、无效2例、总有效率为94.3%；对照组显效12例、好转16例、无效7例、总有效率为80%，两组数据比较有统计学意义（P<0.05）。结论血脂康治疗急性冠脉综合征临床效果显著，可以有效降低血清超敏C反应蛋白的浓度，协调血脂水平的同时改善血管功能，减少炎性反应的发生，从而提高患者的生存质量，降低病死率。“,” Objective: To investigate the effect of Xuezhikang Capsule on acute coronary syndrome patients with serum high sensitivity C reactive protein. Methods: From 2010 June -2011 year in December in our hospital department of Cardiology treatment in patients with acute coronary syndrome in 70 cases were randomly divided into two groups, the control group was given simvastatin treatment, observation of Xuezhikang Capsule treatment group on the basis of this, 6 months after treatment, the change values were compared between the two groups in serum of patients with clinical curative effect and sensitivity C reactive protein. Results: After treatment the serum high sensitivity C reactive protein and numerical treatment before and after treatment compared with control group, there was statisticaly significant (P<0.05); the improvement of clinical symptoms observation group 19, 15 cases improved, 1 cases ineffective, the total efficiency of 97.1%; control group 13 cases, 17 cases improved, 5 invalid cases, the total effective rate was 85.7%, the data of the two groups were statisticaly significant (P<0.05); electrocardiogram improvement 20 cases were markedly effective, 13 cases improved, 2 cases ineffective, the total efficiency of 94.3%; control group 12 cases, 16 cases were improved, 7 cases ineffective, the total efficiency of 80%, two sets of data there was significant difference (P<0.05). Conclusion: Xuezhikang in treatment of patients with acute coronary syndrome clinical effect is remarkable, can effectively reduce the concentration of serum high sensitivity C reactive protein, blood lipid level and coordination to improve vascular function, reduce inflammatory reaction, so as to improve the quality of life of patients, reduce the mortality rate.